Covid treatments

Monoclonal antibodies therapy
A monoclonal antibodies therapy is derived from Covid-19 survivors’ own antibodies and designed to fight the infection just as the natural immune system would.

External

 * by Lilly
 * and imdevimab, aka Regen-Cov or Ronapreve by Regeneron and Roche
 * by Lilly
 * , aka Lagevrio, by Merck & Co
 * by Pfizer
 * by GSK-Vir Biotechnology

News

 * 13 Nov 2021, Economist.com, New antiviral drugs mark a big turning point in the covid-19 pandemic, The highly effective drugs can be taken as pills
 * 07 Nov 2021, (fr) FranceInfo, Covid-19 : après le molnupiravir, quels sont les autres traitements qui pourraient être bientôt disponibles ?, Outre le molnupiravir, antiviral élaboré par le laboratoire Merck, cinq traitements sont en cours d'élaboration.
 * 04 Nov 2021, Economist.com, An effective new drug to treat covid-19 emerges from Merck, It hopes to make the drug available in poor countries as well as rich ones.
 * 11 Oct 2021, Merck.com, Merck and Ridgeback announce submission of emergency use authorization application to the U.S. FDA for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate covid-19 in at risk adults, If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of covid-19
 * 29 Aug 2021, (fr) FranceInfo, Covid-19 : où en est la recherche de traitements contre la maladie ?, Si la vaccination reste pour l'heure la seule solution pour endiguer la pandémie, plusieurs médicaments sont à l'étude, notamment pour lutter contre les formes graves du Covid-19.
 * 20 Aug 2021, Politico.eu, UK approves first monoclonal antibody treatment for covid-19, The approval is the first step in getting the treatment to patients.The green light from the Medicines and Healthcare products Regulatory Agency (MHRA) for Ronapreve, a drug developed by Regeneron and Roche, is the first step in getting the treatment to patients.
 * 20 Aug 2021, (fr) LesEchos.fr, Covid-19 : AstraZeneca tiendrait un traitement préventif potentiellement efficace, Le laboratoire anglo-suédois présente des résultats préliminaires encourageants d'un essai de phase III de son traitement contre le Covid-19 combinant deux anticorps monoclonaux. Il permettrait de réduire fortement le risque de développer des symptômes chez des personnes fragiles. L'occasion de faire un point sur les différents traitements existants.Ce traitement, réalisé par injection intramusculaire, ne se substitue pas à un vaccin mais agit, comme eux, en prévention de l'infection. Il vise particulièrement les personnes qui « pourraient avoir besoin de davantage qu'un vaccin pour retrouver des vies normales », explique Myron Levin, professeur à l'Université du Colorado aux Etats-Unis et en charge de l'essai.
 * 17 Aug 2021, Politico.eu, The life-saving covid drug doctors can’t use for their most at-risk patients, A major study showed Roche/Regeneron’s antibody cocktail saved lives among people with low immune systems.
 * 28 Jul 2021, Pro.politico.eu, European Commission signs contract for coronavirus monoclonal antibody treatment, The signing of the contract with pharma company GlaxoSmithKline for sotrovimab, which GSK developed with Vir Biotechnology, happened Tuesday.
 * 07 Jul 2021, Politico.eu, WHO backs 2 monoclonal antibodies to treat severe covid-19
 * 21 Jun 2021, Reuters.com, Study confirms GSK-Vir antibody drug reduces hospitalization, death in covid-19 patients
 * 15 Jun 2021, Politico.eu, AstraZeneca’s antibody cocktail fails to protect against coronavirus, AZD7442 — a combination of two different monoclonal antibodies — didn’t achieve a statistically significant reduction in the risk of symptomatic covid-19 after exposure to the virus, failing the primary study objective.
 * 04 May 2021, Politico.eu, Cutting-edge coronavirus antibody drugs get their day in Europe, After the US got an early start, a handful of EU countries have rolled out neutralizing antibodies.